Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AdaptHealth (AHCO)

AdaptHealth names Harriss Currie CFO effective Sept. 9; Jason Clemens departs

Neutral Impact 4 of 5 leadership Written later

AdaptHealth appointed Harriss Currie as Chief Financial Officer, effective September 9, 2026. Jason Clemens, the current CFO, ends his CFO authority on September 8, 2026, and leaves the company effective October 1, 2026, with severance for a termination without cause. The change in the top finance role is a leadership transition; the filing contains no financial results or guidance.

Key points

  • Harriss Currie, age 64, starts as CFO on September 9, 2026, under an employment agreement dated September 7, 2026.
  • Currie's annual base salary is $670,000, with a target bonus of 100% of base salary, and a sign-on RSU grant valued at $818,462.
  • Currie previously served as CFO of Luminex Corp. from October 2003 until its sale to DiaSorin in July 2021.
  • Jason Clemens's CFO authority ends September 8, 2026, and his employment ends October 1, 2026; he will receive severance for a termination without cause.

The filing

CompanyAdaptHealth (AHCO)
Form8-K, current report
Filed with the SECSep 8, 2026, 4:16 PM ET
Accession number0001104659-26-105912

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.